Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01026233 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
Cardiac Safety Study of Brentuximab Vedotin (SGN-35) (NCT01026233)

Trial Description
The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (also known as SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.

This trial is sponsored by Millennium Pharmaceuticals/Seattle Genetics [1]

Study Data

  • Conditions:
    • Hodgkin Disease
    • Anaplastic Large-Cell Lymphoma (ALCL)
    • Non-Hodgkin Lymphoma (NHL)
  • Interventions:
  • Phase: I
  • Enrollment: 52
  • Start: January 2010
  • Completion: August 2011
  • Last verified: December 2014

Study Schematic 

NCT01026233 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 10, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar